Drug Profile
MK 5395
Alternative Names: MK-5395Latest Information Update: 08 Aug 2011
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Neuroprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 08 Aug 2011 No development reported - Phase-I for Neurological disorders in USA (unspecified route)
- 09 Dec 2008 Phase-I clinical trials in Neurological disorders in USA (unspecified route)